Praxis Precision Medicines stock falls 5.55% after mid-stage study results.

• Pomerantz LLP investigating claims against Praxis Precision Medicines. • Allegations of securities fraud or unlawful business practices. • Mid-stage study results for vormatrigine reported on August 4, 2025. • Treatment-emergent adverse events affected 36 of 61 patients. • 24% of participants discontinued the study. • Praxis stock price fell 5.55% to $51.09 per share.

New York, July 2, 2025 — Pomerantz LLP has initiated an investigation into claims on behalf of investors of Praxis Precision Medicines, Inc. (NASDAQ: PRAX). The investigation focuses on whether Praxis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices [1].

On August 4, 2025, Praxis reported its financial results for the second quarter of 2025. Among the disclosed items, Praxis announced mid-stage study results for its anti-seizure medication vormatrigine. The study revealed that 36 out of 61 patients experienced treatment-emergent adverse events, and nearly one in four participants discontinued the study. This news led to a significant drop in Praxis's stock price, which fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025 [1].

Pomerantz LLP, known for its expertise in corporate, securities, and antitrust class litigation, is advising investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to learn more about the investigation and how to potentially join the class action [1].

Investors should closely monitor this development as it could impact Praxis's financial health and regulatory outlook. The recent clinical results and their implications for the company's pipeline and stock price will continue to be a focus for investors and financial professionals.

References:
[1] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-praxis-precision-medicines-inc--ce7c5ed2d18cf725
[2] https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-is-up-after-positive-phase-2
[3] https://www.globenewswire.com/news-release/2025/08/09/3130495/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-on-Behalf-of-Investors-of-Praxis-Precision-Medicines-Inc-PRAX.html